We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Veru

News List

FDA Approves Entadfi Drugs
December 14, 2021
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer...
Veru initiates enrolment in Phase III trial of sabizabulin for Covid-19 pharmaceutical-technology
May 20, 2021
Veru has enrolled the first subject in Phase III clinical trial of sabizabulin to treat hospitalised Covid-19 patients who are at high risk for acute respiratory distress syndrome (ARDS).
Veru to progress Covid-19 drug into Phase III study pharmaceutical-technology
March 03, 2021
Veru is set to advance its drug VERU-111 into a Phase III registration clinical study on hospitalised high-risk Covid-19 patients for obtaining clinically meaningful benefits in the Phase II clinical trial.
Veru reports positive data from Phase II Covid-19 drug trial pharmaceutical-technology
February 10, 2021
Veru has reported positive efficacy and safety results from Phase II clinical trial of an oral drug, VERU-111, in hospitalised Covid-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS).